multicent
studi
clientown
cat
hcm
recent
resolv
chf
within
last
day
random
cat
cat
without
lvoto
cat
receiv
either
pimobendan
mgkg
n
placebo
n
conjunct
furosemid
proport
cat
reach
primari
endpoint
successy
n
pimobendan
placebo
full
analysi
set
popul
n
differ
treatment
group
p
cat
without
lvoto
n
numer
higher
success
rate
pimobendan
n
compar
placebo
n
odd
ratio
ci
wherea
cat
lvoto
n
numer
higher
success
rate
placebo
n
compar
pimobendan
n
odd
ratio
ci
incid
advers
event
compar
treatment
group
p
pimobendan
administr
lead
improv
outcom
studi
addit
endpoint
pivot
studi
identifi
advers
event
occur
infus
aptam
bc
indic
administr
safe
use
dog
estim
median
time
primari
endpoint
significantli
longer
dog
receiv
aptam
day
iqr
day
dog
dcm
control
group
day
iqr
day
log
rank
p
given
pilot
studi
small
studi
popul
remain
necessari
valid
find
largescal
random
doubleblind
placebocontrol
studi
lad
surviv
patient
success
reduc
left
atrial
pressur
greater
patient
one
patient
final
lap
unabl
measur
technic
reason
size
final
balloon
dilat
across
atrial
septum
mm
first
dog
mm
mm
procedur
time
minut
complic
procedur
includ
selflimit
pericardi
effus
arrhythmia
atrial
prematur
complex
atrial
flutter
arrhythmia
either
selflimit
resolv
therapi
dog
three
dog
discharg
follow
day
discharg
day
postprocedur
die
within
hour
procedur
ownerelect
euthanasia
respiratori
failur
sign
left
chf
resolv
surviv
dog
follow
procedur
reduct
diuret
dose
achiev
patient
evid
worsen
pulmonari
hypertens
right
chf
evid
patient
shortterm
followup
month
one
dog
requir
increas
diuret
dose
day
iasd
note
smaller
initi
creat
mm
vs
mm
day
suggest
spontan
closur
respons
chf
dog
develop
recrudesc
pulmonari
edema
day
time
defect
patent
procedur
success
repeat
discharg
follow
day
remain
surviv
dog
free
congest
sign
patent
iasd
time
report
submiss
left
atrial
decompress
result
rapid
reduct
left
atrial
pressur
may
promis
costeffect
therapeut
option
dog
current
medic
therapi
limit
investig
longterm
followup
necessari
determin
appropri
time
patient
select
size
iasd
optim
outcom
discord
antigen
toxin
elisa
result
may
encount
hors
complic
diagnosi
object
studi
evalu
abil
isol
toxigen
c
difficil
antigen
posit
toxin
neg
sampl
fecal
sampl
collect
foal
rang
day
week
age
present
referr
hospit
diarrhea
andor
enter
develop
diarrhea
enter
hospit
sampl
perform
inclus
part
routin
diagnost
test
fecal
sampl
test
c
difficil
use
elisa
detect
c
difficil
antigen
glutam
dehydrogenas
toxin
b
c
diff
quik
chek
complet
techlab
blacksburg
va
usa
studi
period
fecal
sampl
test
c
difficil
fortytwo
yield
antigen
posit
toxin
neg
result
sampl
antigen
posit
toxin
neg
evalu
enrich
cultur
clostridium
difficil
isol
antigen
posit
toxin
neg
sampl
recov
isol
toxigen
possess
gene
encod
toxin
b
clinic
relev
antigen
posit
toxin
neg
result
need
studi
foal
studi
enter
could
consist
cdi
potenti
caus
diseas
identifi
bettina
dunkel
royal
veterinari
colleg
edward
knowl
royal
veterinari
colleg
yumei
chang
royal
veterinari
colleg
nicola
menziesgow
reader
royal
veterinari
colleg
blood
llactat
concentr
higher
poni
gastrointestin
diseas
hors
possibl
due
differ
bodi
condit
bc
therefor
correl
llactat
concentr
measur
bc
investig
healthi
hors
poni
poni
influenc
endocrin
statu
llactat
concentr
also
investig
blood
sampl
obtain
poni
hors
breed
weight
height
measur
bc
llactat
concentr
record
poni
triglycerid
acth
concentr
measur
oral
glucos
test
perform
correl
llactat
bc
paramet
establish
associ
llactat
concentr
equid
type
poni
hors
bc
age
glucos
concentr
investig
multivari
model
weak
p
neg
correl
detect
llactat
concentr
averag
bc
score
r
heart
girth
height
ratio
r
age
r
llactat
glucos
concentr
weakli
correl
r
p
poni
weak
neg
correl
llactat
triglycerid
concentr
detect
r
p
signific
correl
endocrin
paramet
multivari
model
age
ae
p
heart
girth
height
ratio
ae
p
significantli
associ
llactat
repres
reduct
llactat
per
year
increas
age
reduct
llactat
per
unit
increas
heart
girth
height
ratio
age
bc
influenc
blood
llactat
concentr
significantli
weakli
prevent
outbreak
intervent
studi
continu
demonstr
import
rapid
diagnosi
abil
ehv
spread
amongst
differ
wildlif
speci
environ
primarili
water
hole
investig
africa
mongolia
pathogenesi
impact
infect
earli
pregnanc
loss
bloodderiv
mesenchym
stem
cell
report
togeth
immun
respons
nasopharynx
blood
cerebrospin
fluid
follow
experiment
infect
infect
also
show
induc
procoagul
state
endotheli
cell
transport
endotheli
pathogenesi
site
mononuclear
cell
celltocel
spread
demonstr
use
new
flow
chamber
model
diagnost
virolog
role
immun
biomark
nasopharynx
sera
experiment
infect
studi
view
identifi
immun
protect
anim
could
releas
quarantin
lamp
assay
differenti
vs
neuropathogen
vs
nonneuropathogen
biotyp
infect
develop
infect
model
sever
vitro
model
describ
studi
interact
respiratori
epithelium
endotheli
cell
pbmc
reveal
potenti
novel
strategi
futur
therapeut
intervent
vivo
impact
infect
sever
month
infect
reveal
histolog
chang
sever
organ
includ
nervou
system
test
eye
immun
therapi
import
intranas
immun
primarili
mediat
igg
isotyp
describ
impact
gd
gene
delet
vs
infect
pathogenesi
report
sever
studi
explor
develop
cellular
immun
role
peptid
motif
cytotox
tlymphocyt
specif
virus
thought
global
distribut
import
rare
sporad
diseas
equin
multinodular
pulmonari
fibrosi
respiratori
reproduct
diseas
remain
uncertain
new
realtim
pcr
diagnost
test
vitromodel
epidemiolog
studi
describ
includ
impact
age
distribut
coinfect
respiratori
diseas
coinfect
gastric
mucosa
hospit
hors
typic
discharg
within
day
admiss
subsequ
detect
shed
increas
concern
regard
transmiss
prevent
home
set
order
make
bestpractic
evidencebas
recommend
regard
manag
individu
hors
popul
must
understand
durat
shed
among
affect
hors
vital
part
epidemiolog
salmonella
equin
popul
end
object
studi
character
durat
salmonella
shed
among
cultureposit
hors
describ
factor
associ
shed
durat
investig
advers
effect
creat
exposur
salmonellaposit
hors
stablem
subclin
clinic
affect
hors
cultur
weekli
week
isol
phenotyp
character
survey
conduct
determin
factor
associ
shed
impact
stablem
gener
hors
clinic
salmonellosi
like
intermitt
shed
enterica
fece
greater
median
durat
marefo
pair
tend
parallel
shed
pattern
irrespect
clinic
subclin
shed
result
studi
indic
hors
clinic
salmonellosi
like
pose
greater
risk
environment
contamin
subclin
affect
hors
may
contribut
ongo
transmiss
onfarm
precaut
taken
irrespect
diseas
statu
gunther
van
loon
equin
cardioteam
ghent
univers
dominiqu
de
clercq
equin
cardioteam
ghent
univers
ann
decloedt
equin
cardioteam
ghent
univers
liss
vera
equin
cardioteam
ghent
univers
glenn
van
steenkist
equin
cardioteam
ghent
univers
cm
de
bruijn
wolvega
equin
clinic
margreet
ploeg
depart
pathobiolog
willem
back
utrecht
univers
catherin
delesal
ghent
univers
koen
chier
ghent
univers
aortopulmonari
fistul
apf
extrem
rare
gener
hors
popul
rel
common
friesian
hors
typic
transvers
tear
aorta
occur
near
remnant
ligamentum
arteriosum
format
fistula
toward
pulmonari
arteri
fistul
often
rel
long
irregular
shape
tract
wide
rang
clinic
sign
may
occur
tachycardia
right
heart
failur
pulmonari
hypertens
usual
present
often
holosystol
earli
diastol
murmur
found
dorsal
aortic
valv
area
obtain
good
qualiti
cardiac
ultrasound
imag
may
challeng
friesian
due
bodi
conform
purpos
studi
describ
take
diagnost
ultrasound
imag
apf
applic
equin
practic
data
friesian
geld
mare
mean
bodi
weight
ae
kg
includ
age
rang
year
median
hors
underw
full
echocardiograph
exam
includ
mmode
color
flow
doppler
addit
specif
view
acquir
visual
apf
hors
show
ultrasound
chang
compat
sever
pulmonari
hypertens
decreas
aortic
size
right
parastern
left
ventricular
outflow
tract
view
right
ventricular
rv
inflowoutflow
view
figur
apf
could
visual
triangl
right
atrium
ra
aorta
ao
pulmonari
arteri
pa
hors
lesion
sometim
subtl
color
flow
examin
view
show
abnorm
flow
suggest
apf
hors
one
hors
show
aortic
dissect
circular
pseudoaneur
cuff
entir
visibl
aorta
leftsid
longaxi
view
pa
third
intercost
space
superior
visual
apf
cranial
slight
dorsal
treatment
week
treatment
gastroscop
examin
perform
week
io
hors
anonymis
gastroscopi
imag
review
blind
detail
treatment
noninferior
statist
perform
compar
two
treatment
signific
differ
group
fortyf
hors
eggd
met
inclus
criteria
receiv
io
receiv
oo
lesion
within
pylor
antrum
differ
sever
group
fiftysix
hors
esgd
met
inclus
criteria
receiv
io
receiv
oo
differ
squamou
lesion
distribut
grade
two
treatment
group
treatment
failur
rate
eggd
esgd
present
tabl
inject
omeprazol
found
noninferior
oral
omeprazol
heal
improv
glandular
p
squamou
lesion
p
io
group
signific
improv
compar
pretreat
eggd
esgd
lesion
within
week
given
larg
differ
failur
rate
two
treatment
investig
larger
number
justifi
determin
whether
io
superior
oo
medic
record
hors
admit
emerg
stimul
synthet
acth
perform
review
circi
defin
baselin
cortisol
cortisol
delta
cortisol
variabl
associ
circi
surviv
system
inflammatori
respons
syndrom
sir
presenc
ischem
lesion
investig
p
consid
signific
sixtynin
hors
includ
circi
admiss
addit
develop
circi
hospit
die
sir
ischem
lesion
admiss
hors
circi
higher
acth
concentr
lower
cortisol
delta
cortisol
insulin
concentr
less
like
surviv
p
survivor
lower
acth
cortisol
concentr
admiss
day
higher
poststimul
cortisol
admiss
day
less
like
circi
ischaem
lesion
reflux
p
hors
sir
higher
glucos
concentr
p
hors
ischaem
lesion
higher
acth
cortisol
glucos
concentr
admiss
lower
insulin
concentr
day
like
sir
surviv
p
multivari
analysi
could
fit
outcom
circi
adult
hors
common
character
high
acth
low
cortisol
low
delta
cortisol
associ
nonsurviv
signific
interest
understand
respiratori
microbiom
specif
certain
phenotyp
may
relat
diseas
suscept
dairi
calv
potenti
relev
data
includ
improv
screen
diagnost
develop
respiratori
probiot
mani
survey
studi
perform
first
studi
author
knowledg
investig
short
term
effect
experiment
bacteri
challeng
upper
lower
respiratori
tract
microbiota
purpos
primari
object
studi
evalu
whether
bacteri
composit
divers
characterist
nasopharyng
np
microbiota
protect
pneumonia
follow
experiment
challeng
pasteurella
multocida
secondari
object
studi
evalu
effect
bacteri
challeng
ampicillin
therapi
np
tonsillar
tracheobronchi
lymph
node
lung
microbiota
prewean
dairi
calv
conveni
sampl
healthi
prewean
holstein
bull
calv
mean
age
ae
day
enrol
juli
hous
laboratori
experiment
protocol
approv
institut
anim
care
use
committe
day
acclim
calv
examin
clinic
respiratori
score
rs
lung
ultrasound
score
uss
calv
normal
rs
uss
select
bacteri
challeng
day
challeng
deep
np
swab
collect
next
day
calv
sedat
video
laryngoscop
use
pass
cathet
distal
trachea
ml
cfuml
p
multocida
administ
calv
monitor
interv
rs
uss
uss
show
signific
consolid
second
deep
np
swab
collect
calv
random
receiv
either
ampicillin
trihydr
n
label
dose
x
day
equal
volum
durat
steril
salin
n
two
calv
develop
signific
lung
consolid
follow
bacteri
challeng
includ
treatment
random
calv
monitor
daili
via
rs
uss
day
day
third
deep
np
swab
collect
calv
sedat
euthan
postmortem
sampl
np
tonsil
lung
tracheobronchi
lymph
node
collect
np
swab
tissu
sampl
store
c
process
simultan
follow
dna
extract
swab
cm
section
tissu
region
rrna
gene
amplifi
use
pcr
librari
sequenc
use
illumina
miseq
platform
sequenc
cluster
oper
taxonom
unit
use
mothur
taxonomi
divers
data
analyz
rstudio
alpha
divers
compar
use
anova
wilcoxon
rank
sum
test
beta
divers
compar
use
permanova
test
linear
regress
model
fit
evalu
effect
prechalleng
np
divers
characterist
health
outcom
mix
linear
regress
model
fit
calf
random
effect
evalu
effect
sampl
type
ampicillin
treatment
divers
metric
microbiota
rel
abund
ra
bacteri
genera
compar
use
kruskal
walli
test
calv
higher
np
alpha
divers
prechalleng
rs
posit
less
day
p
follow
bacteri
challeng
control
serum
total
protein
day
age
ampicillin
treatment
trial
np
alpha
divers
prechalleng
associ
uss
p
signific
differ
alpha
divers
among
np
swab
collect
p
alpha
divers
differ
third
np
swab
postmortem
tissu
sampl
p
alpha
divers
third
np
swab
postmortem
tissu
sampl
affect
ampicillin
treatment
p
bacteri
challeng
p
beta
divers
differ
three
np
swab
p
third
np
swab
tissu
sampl
p
prior
challeng
top
np
genera
bacteroid
sp
myco
acinetobact
sp
compar
swab
tissu
sampl
p
conclus
increas
np
alpha
divers
protect
clinic
respiratori
diseas
challeng
calv
studi
increas
ra
mycoplasma
sp
associ
rapid
develop
lung
lesion
increas
ra
sharpea
sp
associ
slower
develop
lung
lesion
follow
bacteri
challeng
interestingli
ra
pasteurella
sp
affect
antibiot
treatment
np
swab
postmortem
tissu
sampl
increas
speed
lung
lesion
develop
calv
higher
ra
mycoplasma
sp
may
relat
synergi
challeng
strain
resid
strain
mycoplasma
sp
within
np
sharpea
sp
lactic
acid
bacteria
potenti
antagonist
activ
gram
neg
infect
bacteri
popul
may
partial
inhibit
growth
challeng
strain
multidrug
resist
mdr
emerg
issu
mannheimia
haemolytica
varieti
suscept
test
method
avail
clinic
use
object
studi
compar
result
disk
diffus
broth
microdilut
whole
genom
sequenc
wg
suscept
test
haemolytica
isol
collect
mass
medic
tulathromycin
isol
subject
antimicrobi
suscept
test
disk
diffus
broth
microdilut
whole
genom
sequenc
given
antimicrobi
percentag
isol
classifi
suscept
intermedi
resist
compar
three
method
use
exact
test
margin
homogen
overal
categor
agreement
test
method
rang
lowest
agreement
comparison
broth
microdilut
wg
penicillin
cattl
prior
mass
medic
perfect
agreement
found
ceftiofur
enrofloxacin
florfenicol
oxytetracyclin
gamithromycin
test
method
isol
prior
mass
medic
ceftiofur
enrofloxacin
oxytetracyclin
gamithromycin
tilmicosin
test
method
mass
medic
major
error
fals
suscept
detect
possibl
comparison
prior
mass
medic
comparison
mass
medic
major
error
fals
resist
minor
error
error
detect
comparison
prior
mass
medic
comparison
mass
medic
respect
result
studi
show
discrep
result
differ
suscept
test
method
exist
suggest
need
harmon
suscept
test
method
derek
pharmacokinet
studi
drug
milk
often
limit
due
infrequ
sampl
associ
milk
altern
frequent
sampl
collect
repeat
milk
may
increas
drug
elimin
previou
work
intraven
administ
flunixin
demonstr
continu
sampl
udder
use
ultrafiltr
effect
mean
address
concern
object
studi
continu
sampl
healthi
mastit
quarter
cow
natur
occur
mastiti
compar
drug
concentr
intramammari
infus
ceftiofur
ultrafiltr
probe
place
ultrasound
guidanc
gland
cistern
normal
mastit
quarter
ten
matur
midlact
cow
holstein
jersey
cow
natur
occur
subclin
mastiti
ultrafiltr
probe
secur
caudal
later
aspect
udder
depend
quarter
sampl
ceftiofur
hydrochlorid
mg
spectramast
lc
infus
sampl
quarter
time
hour
ultrafiltr
sampl
collect
hour
post
initi
drug
administr
cow
routin
milk
machin
everi
hour
milk
weight
collect
aliquot
milk
collect
treat
quarter
immedi
prior
milk
milk
conclus
milk
equal
volum
aliquot
mix
assess
drug
concentr
whole
milk
ceftiofur
desfuroylceftiofurrel
metabolit
analyz
ultrahighperform
liquid
chromatographi
tandem
mass
spectrometri
uplcmsm
milk
sampl
asept
collect
treat
quarter
immedi
prior
treatment
day
treatment
aerob
cultur
sampl
obtain
healthi
quarter
infect
quarter
infect
quarter
posit
coagulaseneg
staphylococcu
spp
cn
posit
aureu
posit
streptococcu
uberi
aerococcu
spp
escherichia
coli
six
mastit
quarter
cultur
neg
conclus
studi
one
cn
one
aureu
infect
elimin
healthi
quarter
remain
neg
throughout
studi
conclus
ongo
drug
analysi
determin
impact
mastiti
activ
ceftiofur
concentr
udder
correl
pharmacokinet
paramet
treatment
outcom
conclud
collect
ultrafiltr
sampl
mammari
gland
cow
provid
viabl
mean
continu
assess
drug
concentr
milk
continu
milk
cow
normal
accur
associ
pharmacokinet
paramet
treatment
outcom
canin
degen
myelopathi
dm
share
similar
superoxid
dismutas
human
amyotroph
later
sclerosi
al
brain
microstructur
patholog
quantifi
use
diffus
tensor
imag
dti
al
patient
object
use
dti
character
neurodegen
chang
brain
dm
dog
longitudin
determin
relationship
clinic
sever
brain
dti
perform
baselin
everi
month
fraction
anisotropi
fa
mean
diffus
md
axial
diffus
ad
radial
diffus
rd
calcul
region
interest
specif
white
grey
matter
area
gait
score
normal
tetraplegia
assign
time
scan
dti
valu
compar
gait
score
evalu
time
use
pearson
correl
univari
splitplot
approach
respect
sixteen
dm
dog
includ
mean
age
year
mean
time
onset
sign
first
mri
month
mean
baselin
gait
score
mean
score
chang
baselin
last
scan
fiftyfour
scan
includ
dog
analyz
immunohistochem
express
retrospect
seri
canin
glioma
formalinfix
paraffinembed
tissu
section
glioma
type
grade
immunostain
tumor
addit
stain
accumul
til
within
tumor
pronounc
astrocyt
oligodendrogli
tumor
mean
express
greater
highgrad
glioma
signific
differ
lowgrad
oligodendroglioma
glioblastoma
p
tumor
contain
cell
positivetc
mean
express
increas
grade
consider
higher
astrocyt
tumor
til
observ
case
howev
three
tumor
high
express
til
densiti
consid
posit
positivetil
correl
express
r
p
first
studi
immunohistochem
character
treg
express
axi
canin
glioma
demonstr
spontan
canin
glioma
model
immun
evas
human
counterpart
support
use
canin
glioma
translat
immunotherapeut
studi
part
eight
dog
receiv
mg
xrl
tablet
q
h
day
time
serum
sampl
perform
day
trough
hour
tablet
administr
observ
individu
variat
neither
median
cmax
p
auc
p
significantli
differ
across
sampl
day
use
friedman
test
individu
chang
cmax
rang
median
decreas
serum
levetiracetam
concentr
day
day
median
individu
serum
levetiracetam
concentr
remain
minimum
human
therapeut
interv
point
evalu
clinic
advers
effect
report
dog
conclus
mg
xrl
given
twice
daili
day
result
serum
concentr
clinic
advers
effect
small
cohort
furthermor
signific
differ
serum
levetiracetam
concentr
note
sampl
day
delay
onset
paraplegia
present
rang
minut
day
median
hour
nine
dog
definit
recov
walk
voluntarili
within
mean
day
five
dog
definit
recov
within
month
includ
one
develop
progress
myelomalacia
day
euthanat
one
recov
pain
sensat
could
walk
month
irrevoc
lost
followup
within
month
includ
one
euthanat
day
chang
statu
median
delay
till
present
similar
dog
hour
hour
recov
four
dog
yet
complet
followup
period
strongli
conclus
result
dog
know
outcom
appear
promis
prospect
random
trial
compar
outcom
convent
surgeri
vs
convent
surgeri
plu
extend
durotomi
necessari
defin
valu
intervent
potent
proinflammatori
cytokin
provid
protect
immun
numer
infecti
pathogen
variant
absent
genom
databas
dog
three
pneumocysti
case
six
bank
miniatur
schnauzer
sampl
heterozyg
mutat
allel
frequenc
two
heterozygot
recurr
urinari
tract
infect
other
histori
infecti
diseas
mutat
discov
miniatur
schnauzer
pneumocysti
pneumonia
mutat
incomplet
penetr
could
due
genet
factor
environment
exposur
genet
immunodefici
like
exist
nonminiatur
schnauzer
dog
pneumocysti
partial
h
sequenc
perform
subset
sampl
singl
sampl
test
cluster
ident
sampl
cluster
ident
ident
cluster
three
sampl
cluster
ident
cluster
appar
genet
drift
ident
within
household
subsequ
transmiss
strain
cluster
distinct
three
death
attribut
civ
infect
occur
diagnos
case
older
dog
underli
diseas
civ
also
suspect
least
one
addit
death
civ
introduc
repeatedli
immunolog
popul
howev
contain
measur
appar
effect
demonstr
potenti
valu
prompt
diagnosi
implement
civ
control
measur
felip
do
santo
muniz
unicar
fernanda
triani
gome
de
knegt
unicar
laboratori
pedro
paulo
de
abreu
tele
mina
gerai
feder
univers
allopurinol
increasingli
use
treatment
canin
viscer
leishmaniasi
cvl
format
urinari
xanthin
urolithiasi
relat
possibl
complic
allopurinol
therapi
aim
studi
evalu
incid
urolithiasi
dog
natur
infect
l
infantum
recent
studi
confirm
diet
high
ip
content
neg
impact
felin
renal
health
hypothes
calcium
factor
may
influenc
postprandi
plasma
p
level
potenti
provid
insight
outcom
follow
long
term
exposur
healthi
neuter
cat
fed
singl
exposur
test
meal
daili
energi
requir
crossov
design
trial
last
week
diet
contain
kcal
p
sodium
tripolyphosph
stpp
calcium
phosphoru
ratio
ca
p
postprandi
plasma
p
ioniz
calcium
ica
parathyroid
hormon
pth
measur
serial
via
cephal
cathet
welfar
ethic
review
bodi
compar
diet
g
p
kcal
ca
p
increas
ca
p
reduc
peak
plasma
p
concentr
mmoll
v
mmoll
p
durat
peak
plasma
p
return
baselin
v
p
diet
g
p
kcal
increas
ca
p
prevent
peak
plasma
p
p
pth
follow
pattern
plasma
p
increas
dietari
ca
p
reduc
peak
durat
plasma
p
pth
elev
follow
meal
long
term
feed
trial
confirm
whether
measur
reduc
risk
advers
kidney
chang
butch
rectal
temperatur
previous
correl
analgesia
dog
decreas
baselin
group
hour
drug
administr
significantli
differ
p
group
similar
methadon
plasma
concentr
measur
group
naltrexoneglucuronid
measur
group
dog
measur
dog
group
confirm
naltrexon
administr
naltrexon
ngml
measur
dog
time
point
ngml
measur
dog
conclus
longlast
central
opioid
effect
occur
dog
oral
methadonefluconazol
effect
deterr
human
abusemisus
naltrexon
incorpor
nonsteroid
antiinflammatori
drug
nsaid
mainstay
treatment
musculoskelet
pain
inflamm
speci
hypothes
nsaid
robenacoxib
would
increas
objectivelymeasur
physic
activ
improv
ownerassess
mobil
pain
qualiti
life
tempera
happi
cat
cmsd
otherwis
healthi
cat
n
cmsd
ownerr
impair
enrol
blind
clinic
trial
cat
receiv
placebo
p
baselin
period
random
receiv
placebo
p
robenacoxib
r
two
consecut
treatment
period
treatment
group
ppp
prr
prp
activ
subject
owner
assess
data
collect
data
analyz
use
mixedeffect
gener
linear
model
follow
three
week
treatment
robenacoxib
compar
placebo
result
increas
overal
activ
p
increas
nonzero
activ
p
increas
dusktodawn
activ
p
improv
persist
six
week
withincat
analysi
percentag
cat
higher
activ
receiv
robenacoxib
receiv
placebo
count
p
nonzero
count
p
dusktodawn
activ
p
robenacoxib
treatment
associ
decreas
ownerassess
disabl
significantli
placebo
p
follow
six
week
treatment
signific
improv
tempera
p
happi
p
robenacoxib
advers
effect
occur
similar
frequenc
group
p
data
demonstr
robenacoxib
efficaci
treatment
cmsd
cat
hgm
use
gener
situ
molecular
fingerprint
ffpe
tissu
section
cat
ibd
n
scl
n
case
classifi
either
ibd
scl
base
histopatholog
indic
addit
immunohistochemistri
clonal
test
ffpe
tissu
section
deparaffin
underw
antigen
retriev
subject
ontissu
tryptic
digest
mass
spectra
collect
histopatholog
preselect
area
monomorph
pleomorph
lymphocyt
popul
target
region
linear
discrimin
analysi
classif
algorithm
creat
use
acquir
mass
spectral
data
result
accuraci
perform
intern
cross
valid
assess
total
peak
use
build
model
found
statist
signific
two
group
appli
bonferroni
correct
two
signific
peak
within
mass
spectra
underw
analysi
use
tandem
mass
spectrometri
tent
identifi
beta
actin
histon
express
beta
actin
higher
cat
ibd
histon
express
higher
cat
scl
result
indic
mass
spectrometri
may
power
tool
accur
differenti
felin
scl
ibd
studi
current
progress
valid
result
use
independ
larger
cohort
sampl
alter
microbi
commun
structur
seen
ileal
cecal
content
compar
baselin
longitudin
fece
follow
ursodiol
treatment
specif
ileal
content
microbi
commun
structur
treatment
significantli
differ
baselin
cecal
content
microbi
commun
structur
treatment
significantli
differ
baselin
ileal
cecal
content
member
lachnospiracea
famili
significantli
contribut
alter
observ
use
random
forest
analysi
signific
increas
serum
tauroursodeoxychol
acid
tudca
ursodeoxychol
acid
udca
lithochol
acid
lca
identifi
mice
treat
ursodiol
dose
depend
manner
ileal
content
udca
tudca
significantli
increas
dose
depend
manner
cecal
content
tudca
tcdca
significantli
increas
conclus
ursodiol
administr
convent
mice
result
signific
alter
indigen
gut
microbi
commun
structur
bile
acid
metabolom
studi
first
provid
comprehens
profil
exogen
administ
ursodiol
shape
intestin
ecosystem
studi
investig
chang
turn
modifi
host
physiolog
respons
ongo
veterinari
medicin
ursodiol
routin
administ
howev
ramif
drug
impact
canin
felin
intestin
ecosystem
unknown
addit
studi
elucid
ursodiol
modifi
gut
microbiotabil
acidhost
axi
speci
necessari
indoleaminepyrrol
initi
ratelimit
step
pathway
oxid
tryptophan
kynurenin
express
increas
gastrointestin
tract
human
inflammatori
bowel
diseas
ibd
due
overexpress
proinflammatori
cytokin
activ
tolllik
receptor
increas
express
associ
lower
serum
tryptophan
concentr
human
ibd
due
increas
tryptophan
catabol
dog
proteinlos
enteropathi
ple
decreas
serum
tryptophan
concentr
compar
appar
healthi
dog
howev
express
previous
assess
intestin
mucosa
dog
ple
therefor
studi
aim
determin
signific
differ
mrna
express
duoden
mucosa
dog
ple
compar
healthi
dog
whether
express
correl
serum
tryptophan
concentr
dog
ple
studi
retrospect
studi
use
archiv
paraffinembed
duoden
biopsi
clientown
dog
diagnos
ple
bristol
veterinari
school
previous
serum
tryptophan
concentr
measur
part
separ
studi
healthi
beagl
dog
iowa
state
univers
servic
coloni
novel
rna
situ
hybrid
ish
technolog
rnascop
use
hybrid
mrna
probe
onto
least
duoden
biopsi
tissu
section
dog
rnascop
signal
hscore
visual
use
microscop
singl
oper
perform
quantit
assess
dog
ple
significantli
higher
mrna
express
duoden
mucosa
compar
healthi
control
beagl
dog
